At the highest dose ( @mg ) , evacetrapib significantly inhibited CETP activity ( @ % ) , increased HDL-C ( @ % ) and apo AI ( @ % ) , and decreased LDL-C ( @ % ) and apo B ( @ % ) relative to placebo .